Alligator Bioscience AB (publ) (STO: ATORX)

Market Cap	381.29M
Revenue (ttm)	27.77M
Net Income (ttm)	-248.31M
Shares Out	758.04M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,484,134
Open	0.610
Previous Close	0.579
Day's Range	0.486 - 0.720
52-Week Range	0.403 - 1.568
Beta	1.35
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 58
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2023, Alligator Bioscience AB's revenue was 59.25 million, an increase of 64.58% compared to the previous year's 36.00 million. Losses were -248.59 million, 28.5% more than in 2022.